Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | CRHR1 | P34998 | 15/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3364027 | 0.93 | ALPL (0.47) | CNR1CNR2ALPLCRHR1GABRA2 | |
| Trifluoroacetic Acid SCHEMBL4700422 | 0.88 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL3367293 | 0.87 | CRHR1 (0.48) | CNR1CNR2ALPLCRHR1 | |
| Trifluoroacetic Acid SCHEMBL4698869 | 0.87 | KDM4E (0.40) | CNR1CNR2ALPLCRHR1 | |
| SCHEMBL3363721 | 0.85 | CRHR1 (0.50) | CRHR1 | |
| SCHEMBL14206617 | 0.84 | CRHR1 (0.43) | CNR1CNR2ALPLCRHR1 | |
| SCHEMBL3368898 | 0.84 | CRHR1 (0.50) | ALPLCRHR1 | |
| SCHEMBL3367449 | 0.82 | CRHR1 (0.46) | CNR1ALPLCRHR1 | |
| SCHEMBL3361888 | 0.81 | CRHR1 (0.52) | CRHR1 | |
| SCHEMBL3367536 | 0.80 | CRHR1 (0.49) | CNR1ALPLCRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569911-B1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-02 | — | — | EP | claimed |
| EP-1569911-A1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-07 | — | — | EP | claimed |
| WO-2004050634-A1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-17 | — | — | WO | claimed |
| EP-1569911-B1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-02 | — | — | EP | disclosed |
| US-20070213373-A1 | Indazole derivatives as CRF antagonists | COURNOYER RICHARD L | 2007-09-13 | — | — | US | disclosed |
| US-7214699-B2 | Indazole derivatives as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1569911-A1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004050634-A1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-17 | — | — | WO | disclosed |
| US-20040110815-A1 | Indazole derivatives as CRF antagonists | ROCHE PALO ALTO LLC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213373-A1 | Indazole derivatives as CRF antagonists | CRHR1, CRHR2, CRH | CNR1 6/4885CNR2 14/4885ALPL 4077/4885 |
| US-20040110815-A1 | Indazole derivatives as CRF antagonists | CRHR1, CRHR2, ARRB1 | CNR1 9/4885CNR2 18/4885ALPL 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.